IGC PharmaIGC -2.51%24 Forward PE Ratio is 0.00 as of Jul. 11, 2026. GuruFocus rates IGC with a GF Score™ of 24/100 and a GF Value™ of $0.24 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 354 Biotechnology companies, IGC Pharma ranks worse than 282485.59% on this metric.
IGC Pharma (AMEX:IGC) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
IGC Pharma Forward PE Ratio Related Terms
IGC Pharma Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for IGC Pharma's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IGC Pharma Forward PE Ratio Chart
IGC Pharma Annual Data
Trend
Forward PE Ratio
IGC Pharma Quarterly Data
Forward PE Ratio
IGC vs SER, NRSN, PVCT: Forward PE Ratio Comparison
For the Biotechnology subindustry, IGC Pharma's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IGC Pharma Forward PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IGC Pharma's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where IGC Pharma's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
IGC Pharma (IGC) has a Forward PE Ratio of 0.00 as of Jul. 11, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on IGC Pharma and its competitors. According to the industry distribution chart, IGC Pharma ranks #999999 out of 354 companies in the Biotechnology industry.
Is IGC Pharma's Forward PE Ratio too high?
IGC Pharma's current Forward PE Ratio is 0.00. Based on the distribution chart, IGC Pharma ranks #999999 out of 354 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, IGC Pharma has a GF Score™ of 24/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does IGC Pharma's Forward PE Ratio compare to SER and NRSN?
According to the Biotechnology industry distribution chart, IGC Pharma ranks #999999 out of 354 companies for Forward PE Ratio. This places IGC Pharma in the lower half of its industry. The industry median Forward PE Ratio is 21.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 21.90, based on 354 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on IGC Pharma and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 21.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IGC Pharma's current Forward PE Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IGC Pharma stock overvalued right now?
Based on GuruFocus' analysis, IGC Pharma (IGC) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.24, compared to a current price of $0.27 — trading 13.3% above its estimated fair value. The current Forward PE Ratio is 0.00. IGC Pharma's overall GF Score™ is 24/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For IGC Pharma (IGC), the current Forward PE Ratio is 0.00 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IGC Pharma (IGC) Overvalued in 2026?
Based on GuruFocus' analysis, IGC Pharma stock appears to be overvalued.
The current stock price of $0.27 is trading 13.3% above its estimated GF Value™ of $0.24.
GuruFocus considers IGC Pharma to be Modestly Overvalued.
Key valuation signals for IGC:
Forward PE Ratio: 0.00
GF Value™: $0.24 vs. price of $0.27 (13.3% above fair value)
No single metric tells the full story. See the IGC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
24GF Score
Get the complete analysis for IGC
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IGC has been successfully added to your 